Literature DB >> 17274946

Dopamine D3 receptor ligands: recent advances in the control of subtype selectivity and intrinsic activity.

Frank Boeckler1, Peter Gmeiner.   

Abstract

Various pharmacological studies have implicated the dopamine D(3) receptor as an interesting therapeutic target in the treatment of different neurological disorders. Because of these putative therapeutic applications, D(3) receptor ligands with diverse intrinsic activities have been an active field of research in recent years. Separation of purely D(3)-mediated drug effects from effects produced by interactions with similar biogenic amine receptors allows to verify the therapeutic impact of D(3) receptors and to reduce possible side-effects caused by "promiscuous" receptor interactions. The requirement to gain control of receptor selectivity and in particular subtype selectivity has been a challenging task in rational drug discovery for quite a few years. In this review, recently developed structural classes of D(3) ligands are discussed, which cover a broad spectrum of intrinsic activities and show interesting selectivities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17274946     DOI: 10.1016/j.bbamem.2006.12.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

Review 2.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

3.  Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods.

Authors:  Qi Wang; Robert H Mach; Robert R Luedtke; David E Reichert
Journal:  J Chem Inf Model       Date:  2010-10-11       Impact factor: 4.956

Review 4.  Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.

Authors:  Amy Hauck Newman; Brandi L Blaylock; Michael A Nader; Jack Bergman; David R Sibley; Phil Skolnick
Journal:  Biochem Pharmacol       Date:  2012-07-03       Impact factor: 5.858

5.  Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Peter Grundt; Jianjing Cao; Donna M Platt; Amy Hauck Newman; Roger D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2010-05-21       Impact factor: 4.030

6.  Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.

Authors:  Thomas M Keck; William S John; Paul W Czoty; Michael A Nader; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-03-31       Impact factor: 7.446

7.  Synthesis, Molecular Properties Estimations, and Dual Dopamine D2 and D3 Receptor Activities of Benzothiazole-Based Ligands.

Authors:  Moritz Schübler; Bassem Sadek; Tim Kottke; Lilia Weizel; Holger Stark
Journal:  Front Chem       Date:  2017-09-12       Impact factor: 5.221

8.  Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features.

Authors:  Pengfei Yang; William C Knight; Huifangjie Li; Yingqiu Guo; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ann Clin Transl Neurol       Date:  2020-12-21       Impact factor: 4.511

9.  Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists.

Authors:  Jingbo Xiao; R Benjamin Free; Elena Barnaeva; Jennie L Conroy; Trevor Doyle; Brittney Miller; Marthe Bryant-Genevier; Mercedes K Taylor; Xin Hu; Andrés E Dulcey; Noel Southall; Marc Ferrer; Steve Titus; Wei Zheng; David R Sibley; Juan J Marugan
Journal:  J Med Chem       Date:  2014-04-10       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.